Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenomics.

Literature DB >> 18751198

Pharmacogenomics.

W Sadée¹.

Abstract

Year: 1999 PMID： 18751198 PMCID： PMC1308751

Source DB: PubMed Journal: West J Med ISSN： 0093-0415

× No keyword cloud information.

12 in total

1. Genetic control of isoniazid metabolism in man.

Authors: D A EVANS; K A MANLEY; V A McKUSICK
Journal: Br Med J Date: 1960-08-13

2. Genetic variation as a guide to drug development.

Authors: P W Kleyn; E S Vesell
Journal: Science Date: 1998-09-18 Impact factor: 47.728

Review 3. Genomics and drugs: finding the optimal drug for the right patient.

Authors: W Sadée
Journal: Pharm Res Date: 1998-07 Impact factor: 4.200

Review 4. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Authors: M M Goldenberg
Journal: Clin Ther Date: 1999-02 Impact factor: 3.393

5. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.

Authors: F Broly; A Gaedigk; M Heim; M Eichelbaum; K Morike; U A Meyer
Journal: DNA Cell Biol Date: 1991-10 Impact factor: 3.311

6. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors: B Schmid; J Bircher; R Preisig; A Küpfer
Journal: Clin Pharmacol Ther Date: 1985-12 Impact factor: 6.875

7. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors: H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal: Am J Hum Genet Date: 1996-04 Impact factor: 11.025

8. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors: R M Weinshilboum; S L Sladek
Journal: Am J Hum Genet Date: 1980-09 Impact factor: 11.025

9. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors: J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal: Cancer Res Date: 1998-07-01 Impact factor: 12.701